Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

artículo científico publicado en 2020

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

artículo científico publicado en 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

artículo científico publicado en 2014

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

artículo científico publicado en 2016

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

artículo científico publicado en 2016

CTLA-4 antibodies: new directions, new combinations.

artículo científico publicado en 2014

Checkpoint blocking antibodies in cancer immunotherapy

artículo científico

Checkpoint modulation in melanoma: an update on ipilimumab and future directions

artículo científico publicado en 2013

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

artículo científico publicado en 2013

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

artículo científico publicado en 2014

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

scientific article published on 01 August 2018

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

artículo científico publicado en 2014

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

artículo científico publicado en 2013

Current options and future directions in the systemic treatment of metastatic melanoma

artículo científico

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

scientific article published on 08 April 2016

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

artículo científico publicado en 2014

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

scientific article published on 15 October 2019

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. ⬇️

artículo científico publicado en 2017

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

artículo científico publicado en 2016

Genetic basis for clinical response to CTLA-4 blockade in melanoma

artículo científico publicado en 2014

High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy

artículo científico publicado en 2019

Immune checkpoint modulation: rational design of combination strategies

artículo científico publicado en 2015

Immune modulation in cancer with antibodies

artículo científico publicado en 2013

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

artículo científico publicado en 2015

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy

artículo científico publicado en 2015

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

artículo científico publicado en 2014

Immunologic correlates of the abscopal effect in a patient with melanoma

artículo científico publicado en 2012

Immunomodulatory therapy for melanoma: ipilimumab and beyond

artículo científico publicado en 2013

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

artículo científico publicado en 2017

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement

artículo científico

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

artículo científico publicado en 2012

Ipilimumab for patients with advanced mucosal melanoma

artículo científico publicado en 2013

Liver resection and ablation for metastatic melanoma: A single center experience

artículo científico publicado en 2015

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center

artículo científico publicado en 2015

Mucosal melanoma: pathogenesis, clinical behavior, and management

artículo científico

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

artículo científico publicado en 2017

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

artículo científico publicado en 2015

Nivolumab plus ipilimumab in advanced melanoma

artículo científico publicado en 2013

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

artículo científico

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

artículo científico publicado en 2015

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

artículo científico publicado en 2014

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

artículo científico publicado en 2018

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

artículo científico publicado en 2018

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

artículo científico publicado en 2020

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

artículo científico publicado en 2016

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

artículo científico publicado en 2016

Reply to N. Lowy et al and to J. Dhanda et al.

artículo científico publicado en 2016

Safety of Infusing Ipilimumab Over 30 Minutes

scientific article published on 29 June 2015

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

scientific article published on 05 March 2015

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

artículo científico publicado en 2020

The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas

artículo científico publicado en 2020

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

artículo científico publicado en 2017

Therapeutic implications of KIT in melanoma

artículo científico

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

CTLA-4 antibodies: new directions, new combinations.

Checkpoint blocking antibodies in cancer immunotherapy

Checkpoint modulation in melanoma: an update on ipilimumab and future directions

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

Current options and future directions in the systemic treatment of metastatic melanoma

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. ⬇️

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Genetic basis for clinical response to CTLA-4 blockade in melanoma

High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy

Immune checkpoint modulation: rational design of combination strategies

Immune modulation in cancer with antibodies

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

Immunologic correlates of the abscopal effect in a patient with melanoma

Immunomodulatory therapy for melanoma: ipilimumab and beyond

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

Ipilimumab for patients with advanced mucosal melanoma

Liver resection and ablation for metastatic melanoma: A single center experience

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center

Mucosal melanoma: pathogenesis, clinical behavior, and management

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Nivolumab plus ipilimumab in advanced melanoma

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

Reply to N. Lowy et al and to J. Dhanda et al.

Safety of Infusing Ipilimumab Over 30 Minutes

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

The genetic evolution of treatment-resistant cutaneous, acral and uveal melanomas

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

Therapeutic implications of KIT in melanoma